secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001809519-25-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q1 2025 revenue in-line at $203M; raises FY adjusted EBITDA guidance
---------------------------------------------------------------------------

- Revenue $203.0M, net income $11.1M (net income margin 5.4%).
- Adjusted EBITDA $69.8M (34.4% margin) beat guidance; FY adjusted EBITDA expectations raised.
- Adjusted Net Income $34.4M (16.9% margin).
- Maintains FY 2025 revenue guidance range.
- Over 7 million consumers of prescription-related offerings at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/0001809519-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/gdrx-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001809519-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer